Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea
β Scribed by Furgerson, James L.; Vukelja, Svetislava J.; Baker, W. Jeffrey; O'Rourke, Timothy J.
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 372 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
Essential thrombocythemia (El) Is an uncommon myeloprollferatlve disorder, which is thought to develop from a multlpotent stem cell. Like other myeloprollferatlve diseases, ET is assoclated with an increased risk of development of acute leukemla (AL). However, the large majority of cases of leukemic transformation in ET are thought to be related to prior therapy, usually radioactive phosphorous or alkylatlng chemotherapy, and the development of AL In ET Is extremely rare In the untreated patient. in this report, two cases of ET which evolved into AL without prior exposure to radiation or alkylatlng agents, and which were treated with long-term hydroxyurea therapy, are described. The first case had cytogenetlc changes In the bone marrow suggestive of therapy-associated leukemia, and the second developed myelodysplastic syndrome on therapy which was llkely chemotherapy-Induced and led to acute leukemia. Prolonged used of hydroxyurea In patients with ET may lead to therapy-associated acute leukemia.
π SIMILAR VOLUMES
## METHODS. Minimum follow-up of 21.6 years for living patients was obtained for 26 patients who received weekly cytarabine and 6-thioguanine maintenance ther-2 University of Minnesota, Minneapolis, Minneapy after achieving complete remission (CR) in the UMMCC study. Minimum sota. follow-up of 7.
## BACKGROUND. Although many studies have been performed to evaluate the prognostic significance of CD34 expression in acute myeloid leukemia (AML), the findings have been inconsistent. In this study, the authors reviewed such previous studies to establish a definite conclusion. ## METHODS. Usi